AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19828031 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting periodontal problems (chewing problem)
Number of subjects: 877
Study 19828031 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting periodontal problems (toothache)
Number of subjects: 877
Study 16721192 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedy No‐Shift‐Lag
Number of subjects: 0
Study 16721192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15587753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefcapene pivoxil (CFPN-PI; 450 mg/day)
Number of subjects: 171
Study 15587753 — intervention group
Group type: COMPARATOR
Intervention: Cefteram pivoxil (CFTM-PI; 600 mg/day)
Number of subjects: 171
Study 10828762 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic kidney disease (PKD)
Number of subjects: 886
Study 10828762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis (CGN)
Number of subjects: 886
Study 10828762 — intervention group
Group type: COMPARATOR
Intervention: Other nephropathies
Number of subjects: 886
Study 9293055 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 100 micrograms b.d. via Accuhaler/Diskus inhaler (n = 159)
Number of subjects: 323
Study 9293055 — intervention group
Group type: COMPARATOR
Intervention: BUD 200 micrograms b.d. via Turbohaler inhaler (n = 164)
Number of subjects: 323
Study 9293055 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuhaler/Diskus inhaler
Number of subjects: 323
Study 9293055 — intervention group
Group type: COMPARATOR
Intervention: Turbohaler inhaler
Number of subjects: 323
Study 8227491 — intervention group
Group type: EXPERIMENTAL
Intervention: CGI severity ratings
Number of subjects: 116
Study 8227491 — intervention group
Group type: EXPERIMENTAL
Intervention: CGI improvement ratings
Number of subjects: 116
Study 3514075 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 93
Study 3514075 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 93
Study 3396372 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic treatment table
Number of subjects: 65
Study 3396372 — intervention group
Group type: COMPARATOR
Intervention: Conventional bed
Number of subjects: 65
Study 31694732 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol
Number of subjects: 30
Study 31694732 — intervention group
Group type: EXPERIMENTAL
Intervention: Quaternary ammonia or biguanide disinfectant
Number of subjects: 30
Study 31694732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet germicidal irradiation (UVGI)
Number of subjects: 30
Study 29533115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 2,000 IU daily with standard chemotherapy
Number of subjects: 72
Study 29533115 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 72
Study 28152221 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoma cloths
Number of subjects: 18
Study 28152221 — intervention group
Group type: EXPERIMENTAL
Intervention: HMEs with stoma cloths
Number of subjects: 18
Study 26314808 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive skin-prick test (SPT) for aeroallergens
Number of subjects: 1583
Study 26314808 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis (AD) diagnosis
Number of subjects: 1583
Study 26314808 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SPT for aeroallergens
Number of subjects: 1583
Study 23423452 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiquette-based medicine (EtBM) behaviors performed by hospitalists
Number of subjects: 226
Study 23423452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting down during patient interaction
Number of subjects: 226
Study 23423452 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiquette-based medicine scores
Number of subjects: 226
Study 21219197 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amino acid supplementation (4 g thrice a day) for 3 months
Number of subjects: 30
Study 21219197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 18421537 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 113
Study 16531445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (i.v. 250 microg kg(‐1))
Number of subjects: 54
Study 16531445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 54
Study 12562650 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene
Number of subjects: 321
Study 12562650 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 321
Study 10946983 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oxygen-permeable soft lens (CIBAVision Focus/NIGHT & DAY, Dk/t= 175)
Number of subjects: 2
Study 10946983 — intervention group
Group type: COMPARATOR
Intervention: Control (no lens)
Number of subjects: 2
Study 9140792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg)
Number of subjects: 34
Study 9140792 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10-20 mg)
Number of subjects: 34
Study 1580094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides 500 mg (normal volunteers)
Number of subjects: 59
Study 1580094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides 1000 mg (patients with venous hypertension and diabetic microangiopathy)
Number of subjects: 59
Study 3907343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid and tobramycin
Number of subjects: 50
Study 3907343 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin, tobramycin, and vancomycin
Number of subjects: 50
Study 3907343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid
Number of subjects: 50
Study 3907343 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 50
Study 29667902 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia
Number of subjects: 60
Study 29667902 — intervention group
Group type: COMPARATOR
Intervention: conventional blood cardioplegia
Number of subjects: 60
Study 27317617 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste Lessons Vegetable Menu (TLVM: TL with 3 added experiential learning activities)
Number of subjects: 800
Study 27317617 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste Lessons (TL: 5 lessons)
Number of subjects: 800
Study 27317617 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste Lessons Vegetable Menu (TLVM)
Number of subjects: 800
Study 27317617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study 24290404 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised pelvic floor muscle training
Number of subjects: 447
Study 24290404 — intervention group
Group type: COMPARATOR
Intervention: Prolapse lifestyle advice leaflet and no muscle training (control group)
Number of subjects: 447
Study 22434360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2)
Number of subjects: 795
Study 22434360 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin (75 mg/m2)
Number of subjects: 795
Study 22434360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin
Number of subjects: 795
Study 22434360 — intervention group
Group type: COMPARATOR
Intervention: Placebo-cisplatin
Number of subjects: 795
Study 22434360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin (performance status 0 or 1)
Number of subjects: 795
Study 22434360 — intervention group
Group type: COMPARATOR
Intervention: Placebo-cisplatin (performance status 0 or 1)
Number of subjects: 795
Study 22434360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin (oropharyngeal cancers)
Number of subjects: 795
Study 22434360 — intervention group
Group type: COMPARATOR
Intervention: Placebo-cisplatin (oropharyngeal cancers)
Number of subjects: 795
Study 21046369 — intervention group
Group type: COMPARATOR
Intervention: Anodal direct current stimulation (tDCS)
Number of subjects: 0
Study 21046369 — intervention group
Group type: COMPARATOR
Intervention: Cathodal direct current stimulation (tDCS)
Number of subjects: 0
Study 21046369 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 21046369 — intervention group
Group type: COMPARATOR
Intervention: Pre stimulation
Number of subjects: 0
Study 17934839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 15976248 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling with sodium azulene sulfonate (Azunol) 4 mg diluted with 100 mL tap water (40 microg/mL)
Number of subjects: 40
Study 15976248 — intervention group
Group type: COMPARATOR
Intervention: Gargling with tap water (control)
Number of subjects: 40
Study 15976248 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling with sodium azulene sulfonate (Azunol)
Number of subjects: 40
Study 11466189 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg fluticasone twice daily (group F)
Number of subjects: 52
Study 11466189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 52
Study 9738225 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (5 x 3.3 Gy irradiation)
Number of subjects: 93
Study 9738225 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 93
Study 9738225 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 93
Study 8032826 — intervention group
Group type: EXPERIMENTAL
Intervention: Education package (test group)
Number of subjects: 124
Study 8032826 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education package)
Number of subjects: 124
Study 2604508 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic doses of vitamin D during the first 3 months of LT4 treatment
Number of subjects: 19
Study 2604508 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D during the first 3 months of LT4 treatment
Number of subjects: 19
Study 2604508 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 19
Study 31331577 — intervention group
Group type: EXPERIMENTAL
Intervention: MA+SSRIs
Number of subjects: 477
Study 31331577 — intervention group
Group type: EXPERIMENTAL
Intervention: EA+SSRIs
Number of subjects: 477
Study 31331577 — intervention group
Group type: COMPARATOR
Intervention: SSRIs alone
Number of subjects: 477
Study 28385154 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) treatment
Number of subjects: 320
Study 28385154 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of PZQ
Number of subjects: 320
Study 28385154 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-infection rates
Number of subjects: 320
Study 28385154 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate
Number of subjects: 320
Study 26815880 — intervention group
Group type: EXPERIMENTAL
Intervention: MR‐proANP levels in the high normal range
Number of subjects: 2243
Study 24518967 — intervention group
Group type: EXPERIMENTAL
Intervention: Palisade sacroiliac joint radiofrequency neurotomy (PSRN)
Number of subjects: 155
Study 24518967 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (400 mg/day for 24 weeks)
Number of subjects: 155
Study 21983370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel-down approach (n = 169)
Number of subjects: 338
Study 21983370 — intervention group
Group type: COMPARATOR
Intervention: Bevel-up approach (n = 169)
Number of subjects: 338
Study 19754867 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment (twice weekly as maintenance treatment)
Number of subjects: 257
Study 19754867 — intervention group
Group type: COMPARATOR
Intervention: Emollient vehicle (standard treatment)
Number of subjects: 257
Study 19754867 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment (twice daily during OLP)
Number of subjects: 257
Study 17973696 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day training program on essential newborn care for doctors, nurses, and midwives in two hospitals
Number of subjects: 892
Study 17973696 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 892
Study 15365536 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus colonization in CRS
Number of subjects: 232
Study 15365536 — intervention group
Group type: COMPARATOR
Intervention: S. aureus colonization in control subjects
Number of subjects: 232
Study 15365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Facultative pathogens in CRS
Number of subjects: 232
Study 15365536 — intervention group
Group type: COMPARATOR
Intervention: Facultative pathogens in control subjects
Number of subjects: 232
Study 15365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway symptoms in CRS
Number of subjects: 232
Study 15365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory tract infections in CRS
Number of subjects: 232
Study 15365536 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus colonization and severity of symptoms
Number of subjects: 232
Study 11591950 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 40
Study 11591950 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 40
Study 9586877 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF(P)TH
Number of subjects: 195
Study 9586877 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 195
Study 7988813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g intravenous infusion 15 minutes before ERCP
Number of subjects: 100
Study 7988813 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 100
Study 2686711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol twice daily (N = 55)
Number of subjects: 172
Study 2686711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol once daily (N = 40)
Number of subjects: 172
Study 2686711 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (N = 53)
Number of subjects: 172
Study 30881904 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1%
Number of subjects: 90
Study 30881904 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.2%
Number of subjects: 90
Study 30881904 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.5%
Number of subjects: 90
Study 28279843 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential exposure to texting while walking in a virtual reality environment
Number of subjects: 219
Study 28279843 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to the intervention)
Number of subjects: 219
Study 25858103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with tamoxifen
Number of subjects: 5
Study 25858103 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT)
Number of subjects: 5
Study 25858103 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) plus chemotherapy (CT)
Number of subjects: 5
Study 23460569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 30
Study 23460569 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 30
Study 23460569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 21527905 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-warmer mattress (TWM)
Number of subjects: 102
Study 21527905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 19878781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal cream (Promiseb Topical Cream)
Number of subjects: 77
Study 19878781 — intervention group
Group type: COMPARATOR
Intervention: Desonide cream 0.05%
Number of subjects: 77
Study 16872785 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic play intervention
Number of subjects: 203
Study 16872785 — intervention group
Group type: COMPARATOR
Intervention: Routine information preparation (Control)
Number of subjects: 203
Study 15482086 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational telephone intervention plus self-help workbook
Number of subjects: 67
Study 15482086 — intervention group
Group type: COMPARATOR
Intervention: Self-help workbook only
Number of subjects: 67
Study 11794547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood and Feelings Questionnaire (MFQ)
Number of subjects: 2560
Study 8733329 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate bid at a dose of 25/3.6mg/kg/day for 7 days
Number of subjects: 437
Study 8733329 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate tid at a dose of 20/5mg/kg/day for 7 days
Number of subjects: 437
Study 2253536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally four times a day
Number of subjects: 12
Study 7001486 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg protacine, 3-times daily, orally, for 10 days
Number of subjects: 40
Study 7001486 — intervention group
Group type: COMPARATOR
Intervention: 50 mg indomethacin, 3-times daily, orally, for 10 days
Number of subjects: 40
Study 7001486 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg protacine, 3-times daily, orally, for 18 days
Number of subjects: 40
Study 7001486 — intervention group
Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone, 3-times daily, orally, for 18 days
Number of subjects: 40
Study 30006887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived group
Number of subjects: 0
Study 30006887 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30006887 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (after a full night of sleep)
Number of subjects: 0
Study 30087016 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Fun program
Number of subjects: 511
Study 30087016 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal curriculum)
Number of subjects: 511
Study 28365372 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 191
Study 28365372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 28365372 — intervention group
Group type: COMPARATOR
Intervention: Opioid blockade (naloxone)
Number of subjects: 191
Study 25885657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition, physical activity, and healthy weight intervention for 50-69 year-olds.
Number of subjects: 500
Study 25885657 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (no intervention).
Number of subjects: 500
Study 24655694 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted provider feedback intervention (quarterly reports on BP control rates)
Number of subjects: 3000
Study 24655694 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted provider feedback intervention
Number of subjects: 3000
Study 22453003 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (150 or 300 mg/day)
Number of subjects: 44
Study 22453003 — intervention group
Group type: COMPARATOR
Intervention: Control (no acarbose)
Number of subjects: 44
Study 20038734 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel and capecitabine (HTX)
Number of subjects: 222
Study 20038734 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel (HT)
Number of subjects: 222
Study 19094763 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 11.25 mg (one injection)
Number of subjects: 127
Study 19094763 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin 3.75 mg (three injections at 28-day intervals)
Number of subjects: 127
Study 19094763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 127
Study 15961681 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (0.16 micromol/kg min)
Number of subjects: 0
Study 15961681 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 0
Study 12626215 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg daily plus estradiol valerate 2 mg daily
Number of subjects: 50
Study 12626215 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus estradiol valerate 2 mg daily
Number of subjects: 50
Study 10050868 — intervention group
Group type: COMPARATOR
Intervention: 500 mg oltipraz weekly
Number of subjects: 234
Study 10050868 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg oltipraz daily
Number of subjects: 234
Study 8927288 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg/day for six months
Number of subjects: 30
Study 8927288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1361968 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 0
Study 1361968 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study 6507769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose‐1,6‐diphosphate (FDP)
Number of subjects: 39
Study 6507769 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (sal)
Number of subjects: 39
Study 31213040 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/h BEI + 10 mL/h PIEB
Number of subjects: 120
Study 31213040 — intervention group
Group type: COMPARATOR
Intervention: 5 mL/h BEI of levobupivacaine 0.125% plus fentanyl 1.45 µg/mL (standard group)
Number of subjects: 120
Study 30423955 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid supplementation (329 mg/day) with 45-minute walking (62.2 +/- 0.9% VO2max)
Number of subjects: 96
Study 30423955 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 45-minute walking (62.2 +/- 0.9% VO2max)
Number of subjects: 96
Study 30423955 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners ingested a double flavonoid dose (658 mg/day) and ran for 2.5 h (69.2 +/- 1.2% VO2max)
Number of subjects: 96
Study 26164110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) plus pharmacotherapy
Number of subjects: 176
Study 25098661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged ankle braces (2 models)
Number of subjects: 17
Study 25098661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhinged ankle brace
Number of subjects: 17
Study 25098661 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no brace)
Number of subjects: 17